Johnson & Johnson Innovation announces collaboration with Singapore Economic Development Board to help transform Singapore’s life science innovation ecosystem

Johnson & Johnson International (Singapore) Pte. Ltd. today announced a collaboration with the Singapore Economic Development Board (EDB) to unlock innovation potential in Singapore’s life sciences ecosystem. This collaboration is the first of its kind and will leverage Johnson & Johnson Innovation – JLABS’ services and innovation resources aimed at boosting the region’s innovation output.

Under this collaboration, JLABS will support early-stage companies with a base in Singapore to help accelerate their early-stage discoveries into innovative medicines, medical technologies, and healthcare solutions. JLABS will also collaborate with local incubators and other strategic partners in the ecosystem on venture and talent development offerings to stimulate employment and commercialization opportunities for early-stage companies.

This collaboration with EDB demonstrates the ongoing commitment of Johnson & Johnson to enable and accelerate the best science and technology in the Asia Pacific region with the ambition of addressing critical unmet medical and healthcare needs. It builds on the success of JLABS’ no-strings-approach and more than a decade of experience, as well as JLABS’ reputation as the largest global network of life science startups, investors, and corporate partners.

Johnson & Johnson Innovation – JLABS and EDB will be co-hosting a symposium in Singapore before the end of the year, with subsequent announcements emerging from this new collaboration. For companies and innovators interested in JLABS, please visit https://jnjinnovation.com/locations/jlabs/jlabs-singapore.